On Might 8, 2026, JW Asset Administration reported promoting 83,600 shares of Liquidia Company (NASDAQ:LQDA)an estimated $3.10 million commerce based mostly on quarterly common pricing.
What occurred
In keeping with an SEC filing dated Might 8, 2026, JW Asset Administration diminished its holdings in Liquidia by 83,600 shares. The estimated transaction worth, calculated utilizing the typical closing worth for the primary quarter of 2026, was $3.10 million. After the commerce, the fund reported holding 16,176 shares value $610,482 at quarter-end. The web place worth decreased by $2.83 million over the interval.
What else to know
-
This was a sale, decreasing the stake to 0.25% of JW Asset Administration’s $243.51 million in reportable U.S. fairness belongings.
-
Prime holdings after the submitting:
-
NASDAQ: EST: $173.84 million (71.4% of AUM)
-
NASDAQ: COCO: $10.47 million (4.3% of AUM)
-
NASDAQ: CPRX: $9.62 million (3.9% of AUM)
-
NASDAQ: GOOGL: $7.90 million (3.2% of AUM)
-
NASDAQ: IREN: $5.64 million (2.3% of AUM)
-
-
As of Might 7, 2026, Liquidia shares have been priced at $42.28, up 175% over the previous yr and vastly outperforming the S&P 500 by roughly 145 share factors.
-
The place was beforehand 1.1% of the fund’s AUM as of the prior quarter.
Firm Overview
|
Metric |
Worth |
|---|---|
|
Market Capitalization |
$3.73 billion |
|
Income (TTM) |
$158.32 million |
|
Web Revenue (TTM) |
$-68.92 million |
Firm Snapshot
-
Liquidia develops and commercializes biopharmaceutical merchandise, together with YUTREPIA (inhaled dry powder treprostinil) and distributes generic treprostinil injection in the USA.
-
The corporate generates income by the sale of proprietary and generic therapies focusing on pulmonary arterial hypertension and associated circumstances.
-
It serves healthcare suppliers and sufferers with unmet medical wants within the U.S. uncommon illness and pulmonary hypertension markets.
Liquidia Company is a biotechnology firm centered on creating and commercializing therapies for pulmonary arterial hypertension and different uncommon ailments. The corporate leverages proprietary drug supply expertise to handle important unmet wants within the U.S. healthcare market.
What this transaction means for traders
This sale in the end appears extra like profit-taking after an explosive run than a whole lack of confidence in Liquidia’s business story, significantly since JW Asset Administration stored a smaller stake at the same time as shares skyrocketed roughly 175% over the previous yr and dramatically outpaced the broader market.
The larger story for long-term traders is that Liquidia is not only a development-stage biotech promising future potential. YUTREPIA, the agency’s inhaled drugs used to deal with hypertension within the lungs, generated $148.3 million in internet product gross sales throughout 2025, together with $90.1 million within the fourth quarter alone, whereas the corporate posted its second consecutive worthwhile quarter. Liquidia additionally ended the yr with $190.7 million in money, up greater than $33 million from the prior quarter.
The corporate stated it has acquired greater than 3,600 prescriptions and handled over 2,900 sufferers since launch. The following vital catalyst is approaching Monday, when the agency is ready to report first-quarter earnings.
